Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens ; volume:04 ; number:01 ; year:2015 ; pages:007-010
South Asian journal of cancer ; 04, Heft 01 (2015), 007-010
- Beteiligte Personen und Organisationen
-
Hingmire, Sachin
Raut, Nirmal
- DOI
-
10.4103/2278-330X.149923
- URN
-
urn:nbn:de:101:1-2021022619151695239574
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hingmire, Sachin
- Raut, Nirmal
Ähnliche Objekte (12)
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study
Serum iron levels increased by cancer chemotherapy correlate the chemotherapy-induced nausea and vomiting
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)
A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting